Drugs / Cyclophonsphamide
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03879577 Background | Nov 2019 → Mar 2023 overdue | HER2 positive breast carcinoma, female breast carcinoma | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03058939 Background | Nov 2018 → Apr 2019 | female breast carcinoma | University of Chicago | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cyclophonsphamide | “Patients with a poor response to docetaxal/herceptin will receive Fluorouracil, Epirubicin Hydrochloride, Cyclophonsphamide (FEC) injection by drip every 3 weeks.” NCT03879577 ↗1“Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)” NCT03058939 ↗ |
| Route | Intravenous | “injection by drip” NCT03879577 ↗ |